Ya meh.. Tapi today turun leh... Boh Lat la

Cepat la Nexggram 0096

BUY BUY BUY

GOOD TIMING TO ADD MORE

Haiz.... Ini EGM apa mau buat ni.. Sokong ke tak sokong

Pak Tua tut tut... Welcome PakTua...

BULL signs

ATTACKKKKMMK

ESPECIALLY WARRANT A, B AND C

OZURA still got a lots of icpt yet to convert... If not mistaken

Trap kat Perak ada la, Bersatu kena trap by Umno

Jangan Lupa Makan Ubat Kaya

TSUNAMI FOR UPTRENDS DAY BY DAY UP UP UP

UMNO sekarang bz pasal Perak dan risau pasal Johor

Mmt la

Nexgram unit Vaccines Lab inks Joint Venture Agreement with Rafarma to distribute and manufacture Covid-19 vaccines in Indonesia and ASEAN [3 Dec 2020] News

NEXGRAM released news bagi ozura cabut.... Bila nak bagi kito orang untung sikit beli roti gardinea?

HARAPAN akan menjadi KENYATAAN.
Kita kena bersabar dan tahan sehingga saat terakhir. SHARK akan tolong kita

Hopefully Nexgram will flying ✈ 0096

中国医药集团有限公司（Sinopharm）及北京生物制品研究所（Beijing Institute of Biological Products）共同研发了另一款疫苗BBIBP-CorV。

https://www.malaysiakini.com/news/552310

ORANG KIAN UNTUNG

Lebih satu kosong.. Shall be 0.30/0.35

Lagi... OZURA... 10,000,090

https://www.enanyang.my/node/367789

We all keeping dreaming...

I wonder who is the BIG BUYER

Agreed with Dr. Warrant

Lagi OZURA buang pada 17th November

Kito semua ni kuat mimpi, manatau akan jadi realiti

WORLD
Sinovac's COVID-19 vaccine induces quick immune response: study
The study comes hot on the heels of upbeat news this month from U.S. drugmakers Pfizer and Moderna as well as Russia that showed their experimental vaccines were over 90% effective based on interim data from large, late-stage trials.
Sinovac's COVID-19 vaccine induces quick immune response: study
Reuters


Published at : November 18, 2020Updated at : November 18, 2020 15:44
Sinovac Biotech’s experimental COVID-19 vaccine CoronaVac triggered a quick immune response but the level of antibodies produced was lower than in people who had recovered from the disease, preliminary trial results showed on Wednesday.


While the early to mid-stage trials were not designed to assess the efficacy of CoronaVac, researchers said it could provide sufficient protection, based on their experience with other vaccines and data from preclinical studies with macaques.

The study comes hot on the heels of upbeat news this month from U.S. drugmakers Pfizer and Moderna as well as Russia that showed their experimental vaccines were over 90% effective based on interim data from large, late-stage trials.

CoronaVac and four other experimental vaccines developed in China are currently undergoing late-stage trials to determine their effectiveness in preventing COVID-19.

The Sinovac findings, published in a peer-reviewed paper in medical journal The Lancet Infectious Diseases, came from results in Phase I and Phase II clinical trials in China involving more than 700 participants.

“Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval,” Zhu Fengcai, one of the authors of the paper, said.

“We believe that this makes the vaccine suitable for emergency use during the pandemic,” Zhu said in a statement published alongside the paper.



Researchers said the findings from large, late-stage studies, or Phase III trials, would be crucial to determine if the immune response generated by CoronaVac was sufficient to protect people from the coronavirus infection.

Sinovac is currently running three Phase III trials in Indonesia, Brazil and Turkey.

The results must be interpreted with caution until Phase III results are published, Naor Bar-Zeev, a professor from Johns Hopkins University who was not involved in the study, said.

“But even then, after Phase III trial completion and after licensure, we should prudently remain cautious,” he said.

‘ATTRACTIVE OPTION’

CoronaVac is one of three experimental COVID-19 vaccines China has been using to inoculate hundreds of thousands of people under an emergency use programme.

The two other vaccines in China’s emergency programme, both developed by institutes linked to Sinopharm, and another vaccine from CanSino Biologics, were also shown to be safe and triggered immune responses in early and mid-stage trials, peer-reviewed papers show.



Gang Zeng, a Sinovac researcher involved in the CoronaVac study, said the vaccine could be an attractive option because it can be stored at normal fridge temperatures of 2 to 8 degrees Celsius (36°-46°F) and may remain stable for up to three years.

“(It) would offer some advantages for distribution to regions where access to refrigeration is challenging,” the author said.

Vaccines developed by Pfizer/BioNTech and Moderna use a new technology called synthetic messenger RNA (mRNA) to activate the immune system against the virus and require far colder storage.

Pfizer’s vaccine must be stored and transported at -70C though it can be kept in a normal fridge for up to five days, or up to 15 days in a thermal shipping box. Moderna’s candidate is expected to be stable at normal fridge temperatures for 30 days but for storage of up to six months it needs to be kept at -20C.

CoronaVac is also being considered by Brazil and Indonesia for inoculations in the coming months.

Indonesia has sought emergency authorisation to start a mass vaccination campaign by the end of the year and vaccines produced by Sinovac and China’s Sinopharm are slated to be used in the early stages of the campaign.

Brazil’s Sao Paulo also plans to roll out CoronaVac as early as January and has agreed a supply deal with Sinovac.

China Sinopharm's coronavirus vaccine taken by about a million people in emergency use
No serious adverse reaction has been reported from those who received the vaccine in emergency use, Sinopharm said in an article on social media WeChat, citing Chairman Liu Jingzhen from a recent media interview.
China Sinopharm's coronavirus vaccine taken by about a million people in emergency use
A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the Covid-19 outbreak, in Beijing, China September 5, 2020. Reuters File Photo

bookmark
facebook
twitter
mail
Reuters
Published at : November 19, 2020Updated at : November 19, 2020 18:10Beijing
Nearly one million people have taken an experimental coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm) through the country’s emergency use programme, the firm said late on Wednesday.

China launched the emergency use programme in July, which so far includes three vaccine candidates for essential workers and other limited groups of people even as clinical studies have yet to be completed to prove their safety and efficacy.

No serious adverse reaction has been reported from those who received the vaccine in emergency use, Sinopharm said in an article on social media WeChat, citing Chairman Liu Jingzhen from a recent media interview.

Two vaccine candidates developed by Sinopharm's subsidiary China National Biotec Group (CNBG) and third one developed by Sinovac Biotech SVA.O have been used for the emergency programme.

It’s unclear which vaccine Liu referred to, and Sinopharm was not immediately available to comment.

Sinopharm’s vaccines, which use inactivated virus unable to replicate in human cells to trigger immune responses, require two doses, clinical trial registration data showed.

The experimental vaccines are undergoing Phase 3 clinical trials overseas that have recruited nearly 60,000 people, and blood samples of more than 40,000 participants have been taken 14 days after they took the second dose, the article said citing Liu, without breaking down the numbers for each vaccine.

Hari ni kurang urusniaga, maka ozura tak buang hari ni...

Table 1 Direct Interest Direct Interest Deemed Interest Deemed Interest
Name of Director Number of Shares % of Issued Shares Number of Shares % of Issued Shares
Dato' Yek Siew Lee 54,713,900 2.058 0

中国已有5款疫苗进入三期临床试验，分别为中国医药集团的两款疫苗，科兴的一款疫苗、军科院联合康希诺研发的疫苗，以及安徽智飞龙科马生物制药研发的疫苗。

https://www.chinapress.com.my/?p=2288944

https://www.malaysiakini.com/news/551504?utm_source=dlvr.it&utm_medium=facebook